Nath Bio-Genes (India) Ltd to Approve Q3 and Nine Months Financial Results on 31st January 2026

Nath Bio-Genes (India) Ltd has announced that its Board of Directors will meet on 31st January 2026 to consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ending 31st December 2025. The meeting is scheduled as per Regulation 29 and 33 of the Listing Regulations 2015. The company has closed its trading window for insider trading from 31st December 2025 and it will reopen on 3rd February 2026.